Publications by authors named "Kunal Ranjan Vinayak"
Background: Metastatic breast cancer (MBC) patients have numerous options for treatment. However, it is essential to consider treatments with favorable toxicity profiles and convenient modes of administration. Eribulin has shown effectiveness in aggressive MBC, but there is a lack of sufficient real-world data specific to Indian patients.
View Article and Find Full Text PDFArticle Synopsis
- The study aimed to assess if adding docetaxel (D) to standard chemotherapy regimens improved overall survival (OS) in patients with advanced HER2-negative gastroesophageal junction and gastric adenocarcinomas.
- Out of 324 patients enrolled, the analysis showed that FOLFOX/CAPOX provided a median OS of 10.1 months, while the DOF/DOX regimen resulted in 8.9 months, with no significant survival advantage from the addition of docetaxel (P = .70).
- The study also noted higher rates of severe neutropenia and neuropathy in the DOF/DOX group and identified a surprisingly high incidence of BRCA1 and BRCA2 alterations